Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment

Area of Science:

• Immunology
• Cancer Biology
• Stem Cell Biology

Background:

• Mesenchymal stem cells (MSCs) modulate tissue immunity.
• Murine MSCs use inducible nitric oxide synthase (iNOS), while human MSCs use indoleamine 2,3-dioxygenase (IDO) for immunosuppression.
• This species-specific difference limits the translatability of mouse studies to human diseases.

Purpose of the Study:

• To develop a humanized mouse model to study human MSC-mediated immunomodulation.
• To investigate the role of human IDO in MSCs within tumor microenvironments.
• To explore therapeutic strategies targeting IDO for cancer immunotherapy.

Main Methods:

• Created humanized MSCs (MSC-IDO) by introducing human IDO into murine iNOS(-/-) MSCs.
• Utilized a mouse iNOS promoter to drive inducible IDO expression.
• Assessed MSC-IDO's effects on T-lymphocyte proliferation in vitro.
• Evaluated MSC-IDO's impact on tumor growth and immune cell infiltration in melanoma and lymphoma models in vivo.
• Tested the efficacy of an IDO inhibitor (1-methyl-tryptophan).

Main Results:

• Humanized MSCs (MSC-IDO) suppressed T-lymphocyte proliferation in vitro.
• MSC-IDO promoted tumor growth in melanoma and lymphoma models.
• IDO inhibition reversed the tumor-promoting effects of MSC-IDO.
• MSC-IDO significantly reduced tumor-infiltrating CD8(+) T cells and B cells.
• Demonstrated that IDO-expressing MSCs mediate immune suppression in the tumor microenvironment.

Conclusions:

• Targeting IDO activity is a promising strategy to restore anti-tumor immunity.
• Relieving IDO-mediated immune suppression by MSCs can enhance the efficacy of cancer immunotherapies.
• The humanized model provides valuable insights into human MSC function in vivo.